Behçet's Disease

Rare inflammatory vasculitis · Specialty medication support · Insurance handled

Key Takeaways

Behçet's is a rare chronic inflammatory vasculitis affecting blood vessels throughout the body
Classic features: recurrent mouth sores, genital ulcers, and eye inflammation
Otezla (apremilast) is FDA-approved specifically for Behçet's oral ulcers
Humira (adalimumab) is FDA-approved for uveitis including Behçet's-associated uveitis
BiologicHealthPlus handles insurance and prior authorization for Behçet's specialty medications

What Is Behçet's Disease?

Behçet's disease (Behçet syndrome) is a rare systemic vasculitis characterized by recurrent inflammation of blood vessels of all sizes. The classic clinical triad is recurrent aphthous mouth ulcers, genital ulcers, and uveitis (eye inflammation). It occurs in episodic flares affecting virtually any organ system and is most prevalent along the ancient Silk Road (Turkey, Middle East, Asia).

Symptoms

👄 Mouth Sores

Recurrent painful aphthous ulcers — present in virtually all patients. Last 1–3 weeks and recur frequently.

🔴 Genital Ulcers

Deep, painful ulcers that heal with scarring. Present in ~75% of patients.

👁️ Eye Inflammation

Uveitis in ~50% of patients. Can cause vision loss without treatment.

🩹 Skin Lesions

Acne-like sores, pseudofolliculitis, erythema nodosum, pathergy (skin hypersensitivity).

🦴 Joint Pain

Non-erosive arthritis affecting large joints in 40–70% of patients.

🫁 Other

GI involvement, neurological complications, vascular thrombosis in severe cases.

FDA-Approved and Key Medications

Medication	Indication	Status
Otezla (apremilast)	Oral ulcers in Behçet's	FDA-approved for Behçet's
Humira (adalimumab)	Behçet's uveitis	FDA-approved for uveitis indication
Remicade (infliximab)	Severe refractory Behçet's	Off-label; used in refractory cases
Colchicine	Skin and mucosal lesions	Standard first-line for mild disease

Yes. Otezla (apremilast) is FDA-approved specifically for oral ulcers associated with Behçet's disease — the only drug with this specific indication. Humira (adalimumab) is FDA-approved for uveitis, including Behçet's-associated uveitis. Remicade and other TNF inhibitors are used off-label for severe refractory cases.

Behçet's is typically managed by a rheumatologist, with ophthalmology involvement for eye disease. Given its rarity, academic medical centers with vasculitis expertise are often preferred for complex cases.

Most commercial insurance covers FDA-approved medications for Behçet's (Otezla for oral ulcers, Humira for uveitis) with prior authorization. Off-label use may require more extensive documentation. BiologicHealthPlus handles all Behçet's insurance verification and prior authorization at no charge.

💊 BiologicHealthPlus Supports Behçet's Disease Patients

Insurance verification, prior authorization, and specialty pharmacy support for Humira, Remicade, Otezla, and other Behçet's medications.

Talk to a Pharmacist →

Medical Disclaimer: Educational information only. Behçet's requires specialist management. Last updated: July 2026.